NewTimeSpace News:As of 13:53 on March 16, 2026, the CSI All-Share Pharmaceutical and Healthcare Index (000991) rose 0.19%. Its constituent stocks posted gains across the board, with Haisco Pharmaceutical up 5.91%, Borui Pharmaceutical rising 4.76%, Salubris Pharmaceuticals climbing 4.71%, Sansure Biotech advancing 4.10% and Zejing Pharmaceutical gaining 3.31%. GF CSI All Share Health Care Index ETF(159938) rose 0.31% to a latest price of 0.64 yuan. Over a longer time horizon, as of March 13, 2026, the ETF had a cumulative increase of 2.08% in the past year. (The stocks listed above are only constituent stocks of the index and do not constitute any specific investment recommendation.)

In terms of liquidity, GF CSI All Share Health Care Index ETFrecorded an intraday turnover rate of 0.3% with a trading volume of 15.1532 million yuan. On a longer-term basis, as of March 13, the ETF had an average daily trading volume of 54.4478 million yuan in the past year.

In terms of scale, the latest size of GF CSI All Share Health Care Index ETFreached 5.091 billion yuan. (Data source: Wind)

As of March 13, the net value of GF CSI All Share Health Care Index ETFhad risen 4.35% in the past year. In terms of profitability, as of March 13, 2026, since its inception, the ETF has achieved a maximum monthly return of 22.34%, a longest streak of consecutive monthly gains of 8 months with a cumulative increase of 67.34% during the period, a ratio of up months to down months of 72:63, and an average monthly return of 5.58% in up months. As of March 13, 2026, the ETF has an annualized excess return over the benchmark of 1.30% since its establishment.

In terms of drawdown, as of March 13, 2026, GF CSI All Share Health Care Index ETFhas a relative benchmark drawdown of 0.04% year-to-date.

In terms of fees, the ETF has a management fee rate of 0.50% and a custodian fee rate of 0.10%.

In terms of tracking accuracy, as of March 13, 2026, the ETF had a tracking error of 0.009% in the past month.

From a valuation perspective, the latest price-to-earnings ratio (PE-TTM) of the CSI All-Share Pharmaceutical and Healthcare Index tracked by GF CSI All Share Health Care Index ETFis only 32.44 times, at the 11.36% quantile of the past year. That is to say, the valuation is lower than that in more than 88.64% of the time in the past year, standing at a historical low.

GF CSI All Share Health Care Index ETFclosely tracks the CSI All-Share Pharmaceutical and Healthcare Index. The CSI All-Share Industry Select Index series selects listed companies that meet certain liquidity and market capitalization screening criteria from the CSI All-Share Industry Indices as sample stocks, aiming to reflect the overall performance of representative and investable securities of listed companies in various industries.

Data showed that as of February 27, 2026, the top 10 weight stocks of the CSI All-Share Pharmaceutical and Healthcare Index (000991) were Hengrui Medicine, WuXi AppTec, Mindray Medical, United Imaging Healthcare, Yunnan Baiyao, Aier Eye Hospital, Pientzehuang, NHU Group, Kelun Pharmaceutical and Fosun Pharma, accounting for a total of 39.02% of the index's weight. (The stocks listed above are only constituent stocks of the index and do not constitute any specific investment recommendation.)

Huayuan Securities stated that after a decade of innovative transformation from 2015 to 2025, China's pharmaceutical industry has basically completed the transformation of old and new growth drivers, and innovative drugs in particular have significantly opened up a new growth curve for Chinese pharmaceutical enterprises. Looking ahead to 2026, it remains optimistic about the innovation-driven main line of medical technology, with key focus on innovative drugs, brain-computer interfaces, AI healthcare, surgical robots and other related sectors.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.